(Press-News.org) New Rochelle, NY, May 21, 2014—A targeted gene silencing strategy blocks production of the dysfunctional huntingtin (Htt) protein, the cause of Huntington's disease, a fatal, inherited neurodegenerative disorder. The effectiveness of this RNA interference (RNAi) approach in reducing levels of mutant Htt protein and disease symptoms in a mouse model of the disease is described in Human Gene Therapy, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. The article is available free on the Human Gene Therapy website.
Lisa Stanek and coauthors from Genzyme (Framingham, MA) used an adeno-associated viral (AAV) vector to deliver a targeted nucleic acid sequence called a small interfering RNA (siRNA) into the cells of affected mice. The siRNA selectively binds to the mutated gene, blocking disease-causing Htt production. The authors present data demonstrating the ability to deliver the therapeutic RNAi into the cells, reduce mutant Htt levels, and impact behavioral deficits in the mice without causing any noticeable neurotoxicity, in their article "Silencing Mutant Huntingtin by Adeno-Associated Virus-Mediated RNA Interference Ameliorates Disease Manifestations in the YAC128 Mouse Model of Huntington's Disease."
"The Genzyme group uses state-of-the-art delivery technology and a gene silencing approach to generate very promising preclinical data for Huntington's disease," says James M. Wilson, MD, PhD, Editor-in-Chief of Human Gene Therapy, and Director of the Gene Therapy Program, Department of Pathology and Laboratory Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia.
INFORMATION:
About the Journal
Human Gene Therapy, the official journal of the European Society of Gene and Cell Therapy, British Society for Gene and Cell Therapy, French Society of Cell and Gene Therapy, German Society of Gene Therapy, and five other gene therapy societies, is an authoritative peer-reviewed journal published monthly in print and online. Human Gene Therapy presents reports on the transfer and expression of genes in mammals, including humans. Related topics include improvements in vector development, delivery systems, and animal models, particularly in the areas of cancer, heart disease, viral disease, genetic disease, and neurological disease, as well as ethical, legal, and regulatory issues related to the gene transfer in humans. Its sister journals, Human Gene Therapy Methods, published bimonthly, focuses on the application of gene therapy to product testing and development, and Human Gene Therapy Clinical Development, published quarterly, features data relevant to the regulatory review and commercial development of cell and gene therapy products. Tables of content for all three publications and a free sample issue may be viewed on the Human Gene Therapy website.
About the Publisher
Mary Ann Liebert, Inc., publishers is a privately held, fully integrated media company known for establishing authoritative peer-reviewed journals in many areas of science and biomedical research, including Nucleic Acid Therapeutics, Tissue Engineering, Stem Cells and Development, and Cellular Reprogramming. Its biotechnology trade magazine, Genetic Engineering & Biotechnology News (GEN), was the first in its field and is today the industry's most widely read publication worldwide. A complete list of the firm's 80 journals, books, and newsmagazines is available on the Mary Ann Liebert, Inc., publishers website.
Novel RNAi therapy silences mutated Huntington's disease gene and reduces symptoms
2014-05-21
[Attachments] See images for this press release:
ELSE PRESS RELEASES FROM THIS DATE:
Questions raised about physio for hip osteoarthritis
2014-05-21
Hip osteoarthritis is a prevalent and costly chronic musculoskeletal condition. Clinical guidelines recommend physiotherapy as treatment, although its effectiveness has never been proven.
Now, a study led by the University's Professor Kim Bennell has found that among adults with painful hip osteoarthritis, physical therapy does not produce greater improvements in pain or function compared with a placebo treatment.
In an article published in the prestigious Journal of the American Medical Association, Professor Bennell and her colleagues randomly assigned patients with ...
In your genes: Family history reveals predisposition to multiple diseases
2014-05-21
The family history screening questionnaire can be used to provide insight into people's susceptibility to breast, ovarian, bowel and prostate cancer, melanoma, ischaemic heart disease and type 2 diabetes.
These findings will lead to greater insight into the process of preventative treatment for cancer in primary care and provide a cost-effective intervention for tailored disease prevention in Australian primary care..
Lead researcher Professor of Primary Care Cancer Research at the University of Melbourne Jon Emery said this research is the first of its kind to validate ...
Finnish researchers discovered a new anticancer compound
2014-05-21
A team of research scientists from VTT Technical Research Centre of Finland, the University of Turku and the University of Eastern Finland has discovered a previously unknown Cent-1 molecule that kills cancer cells. Their research also shows that new cancer drug candidates can be identified faster and at lower cost by using computer-assisted and cell-based screening of compounds.
The objective of the research project led by Marko Kallio, Principal Scientist at VTT, was to accelerate the drug development process by identifying new compounds that would possess similar binding ...
Personalizing revascularization strategy for STEMI patients is vital, EuroPCR panel finds
2014-05-21
21 May 2014, Paris, France: A Great Debate at EuroPCR 2014 saw experts discussing the role of the two most valuable strategies to save the lives of ST-segment Elevation Myocardial Infarction (STEMI) patients: primary percutaneous coronary intervention (PCI) and thrombolysis.
Both these are effective treatments that actively save lives, and when there is no option for primary percutaneous coronary intervention, thrombolysis is the way to proceed, participants heard. The topic of the Great Debate, 'Primary PCI for STEMI: an emergency!' was selected ahead of the session ...
EuroPCR 2014 showcases technological advances in complex cardiovascular interventions
2014-05-21
St Jude Medical's Nanostim device and Medtronic's Micra, both single-chamber leadless pacing systems, and the most advanced commercially available valve, the Edwards Sapien 3 Transcatheter Heart Valve (Edwards Life Sciences) featured in the discussions.
With regard to leadless pacing, participants heard that there was a need for a novel system that provides reliable pacing and sensing, and addresses the challenges of current pacing systems by minimising the risks of infection, pneumothorax, dislodgement and long-term infection.
Prof Panos Vardas, University Hospital ...
Laser light needs more bass
2014-05-21
They shed light on atomic and molecular processes: ultrashort laser pulses are required to study extremely fast quantum phenomena. For years, scientists have been trying to tune the shape of light waves so as to, for instance, steer an electron on exactly the right path. At the TU Vienna, an extraordinarily powerful new method to influence the shape of the laser light wave has been developed in cooperation with the Imperial College in London and the Max-Born-Institute in Berlin. Much like the characteristic sound of a musical instrument, which results from the combination ...
Research breakthrough paves the way for understanding serious diseases
2014-05-21
A few years ago researchers described a Turkish family whose family members moved around on all fours. It turned out that they lacked the sense of equilibrium. This was caused by the rare neurological disease CAMRQ, which is the result of a mutation in the lipid pump in the cells. On the other hand, it was not known why the genetic error had such serious consequences.
The discovery provided inspiration for a Danish study of the mechanism for the vital lipid pump function, the so-called flippase, which transports lipids in the membrane that surrounds every single cell ...
Dolutegravir in HIV-1 infection: Added benefit in adult patients
2014-05-21
Dolutegravir has been approved since January 2014 in combination with other antiretroviral drugs for the treatment of human immunodeficiency virus (HIV) infected adults and adolescents above 12 years of age. In an early benefit assessment pursuant to the Act on the Reform of the Market for Medicinal Products (AMNOG), the German Institute for Quality and Efficiency in Health Care (IQWiG) now examined whether the new drug offers an added benefit over the appropriate comparator therapy.
The dossier compiled by the drug manufacturer provided proof of a considerable added ...
EORTC to present cancer research results at ASCO 2014
2014-05-21
The EORTC will present nine abstracts at the ASCO 2014 Annual Meeting which will be held 30 May – 03 June 2014 in Chicago, Illinois. Four abstracts will be presented in Oral Abstract Sessions, one in a Poster Highlights Session, and another four in General Poster Sessions.
Oral Abstract Sessions
Abstract # 4500
Monday, 02 June, 9:45 – 9:57, E Hall D1
Cora N. Sternberg, Iwona Skoneczna, J.M.Kerst, Sophie Fossa, Peter Albers, Mads Agerbaek, Herlinde Dumez, Maria De Santis, Christine Theodore, Michael Leahy, J.D. Chester, Antony Verbaeys, Armelle Caty, Gedske Daugaard, ...
The Net Children Go Mobile Project launches its report at the ICA 64th Annual Conference
2014-05-21
Washington, DC (May 21, 2014) The Net Children Go Mobile project will release new data on children's mobile use at the 64th Annual Conference of the International Communication Association at the Seattle Sheraton hotel. The project found that 46% of children own a smartphone and 41% use it daily to go online, while 20% own a tablet but 23% use it on a daily basis to access the Internet. Smartphone and tablet users engage more in communication and entertainment activities. They also have a higher level of digital skills, safety skills, and communicative abilities. However, ...